Inactivated rotavirus vaccine induces protective immunity in gnotobiotic piglets

Vaccine

Volumn 28, Issue 33, 2010, Pages 5432-5436

  Wang, Yuhuan ^a   Azevedo, Marli ^b   Saif, Linda J ^b   Gentsch, Jon R ^a   Glass, Roger I ^a,c   Jiang, Baoming ^a  

^a CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^b OHIO STATE UNIVERSITY   (United States)

^c NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

CDC 9; Inactivated rotavirus vaccine; Piglets

Indexed keywords

ALUMINUM PHOSPHATE; IMMUNOGLOBULIN G ANTIBODY; INACTIVATED VIRUS VACCINE; NEUTRALIZING ANTIBODY; ROTAVIRUS VACCINE;

ANIMAL CELL; ANIMAL CELL CULTURE; ANIMAL EXPERIMENT; ANTIBODY TITER; ARTICLE; DRUG EFFICACY; DRUG FORMULATION; DRUG SYNTHESIS; ENZYME LINKED IMMUNOSORBENT ASSAY; GNOTOBIOTICS; IMMUNITY; IMMUNIZATION; IMMUNOGENICITY; NONHUMAN; PIGLET; PRIORITY JOURNAL; ROTAVIRUS INFECTION; VERO CELL; VIRUS SHEDDING;

ANIMALS; ANTIBODIES, VIRAL; DISEASE MODELS, ANIMAL; FEMALE; HUMANS; MATERNAL-FETAL EXCHANGE; MILK, HUMAN; PREGNANCY; ROTAVIRUS; ROTAVIRUS INFECTIONS; ROTAVIRUS VACCINES; SWINE; VACCINES, INACTIVATED;

EID: 77955057194     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2010.06.006     Document Type: Article

References (37)

1. Parashar U.D., Gibson C.J., Bresse J.S., Glass R.I., Parashar U.D., Gibson C.J., et al. Rotavirus and severe childhood diarrhea. Emerging Infectious Diseases 2006, 12:304-306.
2. Ruiz-Palacios G.M., Perez-Schael I., Velazquez F.R., Abate H., Breuer T., Clemens S.C., et al. Safety and efficacy of an attenuated vaccine against severe rotavirus gastroenteritis. New England Journal of Medicine 2006, 354:11-22.
3. Vesikari T., Matson D.O., Dennehy P., Van Damme P., Santosham M., Rodriguez Z., et al. Safety and efficacy of a pentavalent human-bovine (WC3) reassortant rotavirus vaccine. New England Journal of Medicine 2006, 354:23-33.
4. Patel M.M., Shane A.L., Parashar U.D., Jiang B., Gentsch J.R., Glass R.I. Oral rotavirus vaccines: how well will they work where they are needed most?. Journal of Infectious Diseases 2009, 200:S39-48.
5. Patriarca P.A., Wright P.F., John T.J. Factors affecting the immunogenicity of oral poliovirus vaccine in developing countries: review. Reviews of Infectious Diseases 1991, 13:926-939.
6. Su-Arehawaratana P., Singharaj P., Taylor D.N., Hoge C., Trofa A., Kuvanont K., et al. Safety and immunogenicity of different immunization regimens of CVD 103-HgR live oral cholera vaccine in soldiers and civilians in Thailand. Journal of Infectious Diseases 1992, 165:1042-1048.
7. Hanlon P., Marsh V., Shenton F., Jobe O., Hayes R., Whittle H.C., et al. Trial of an attenuated bovine rotavirus vaccine (RIT 4237) in Gambian infants (letter). Lancet 1987, 1:1342-1345.
8. De Mol P., Zissis G., Butzler J.P., Mutwewingabo A., Andre F.E. Failure of live, attenuated oral rotavirus vaccine (letter). Lancet 1986, 2:108.
9. Madhi S.A., Cunliffe N.A., Steele D., Witte D., Kirsten M., Louw C., et al. Effect of human rotavirus vaccine on severe diarrhea in African infants. New England Journal of Medicine 2010, 362:289-298.
10. Patel M., Pedreira C., De Oliveira L.H., Tate J., Orozco M., Mercado J., et al. Association between pentavalent rotavirus vaccine and severe rotavirus diarrhea among children in Nicaragua. JAMA 2009, 301:2243-2251.
11. Jiang B., Gentsch J.R., Glass R.I., Jiang B., Gentsch J.R., Glass R.I. Inactivated rotavirus vaccines: a priority for accelerated vaccine development. Vaccine 2008, 26:6754-6758.
12. Plotkin SL, Plotkin SA. A Short History of Vaccination. In: S.A. Plotkin and W.A. Orenstein, editor. Vaccines. Fourth edition. Philadelphia: Saunders, 2004.
13. Jiang B., Estes M.K., Barone C., Barniak V., O'Neal C.M., Ottaiano A., et al. Heterotypic protection from rotavirus infection in mice vaccinated with virus-like particles. Vaccine 1999, 17:1005-1013.
14. Conner M.E., Crawford S.E., Barone C., Estes M.K. Rotavirus vaccine administered parenterally induces protective immunity. Journal of Virology 1993, 67:6633-6641.
15. Ciarlet M., Crawford S.E., Barone C., Bertolotti-Ciarlet A., Ramikg R.F., Estes M.K., et al. Subunit rotavirus vaccine administered parenterally to rabbits induces active protective immunity. Journal of Virology 1998, 72:9233-9246.
16. McNeal M.M., Rae M.N., Conner M.E., Ward R.L. Stimulation of local immunity and protection in mice by intramuscular immunization with triple- or double-layered rotavirus particles and QS-21. Virology 1998, 243:158-166.
17. Yuan L., Iosef C., Azevedo M.S., Kim Y., Qian Y., Geyer A., et al. Protective immunity and antibody-secreting cell responses elicited by combined oral attenuated Wa human rotavirus and intranasal Wa 2/6-VLPs with mutant Escherichia coli heat-labile toxin in gnotobiotic pigs. Journal of Virology 2001, 75:9229-9238.
18. Jiang B., Wang Y., Saluzzo J.F., Bargeron K., Frachette M.J., Glass R.I., et al. Immunogenicity of a thermally inactivated rotavirus vaccine in mice. Human Vaccines 2008, 4:143-147.
19. Mestas J., Hughes C.C. Of mice and not men: differences between mouse and human immunology. Journal of Immunology 2004, 172:2731-2738.
20. Wang Y., Dennehy P.H., Keyserling H.L., Tang K., Gentsch J.R., Glass R.I., et al. Rotavirus infection alters peripheral T-cell homeostasis in children with acute diarrhea. Journal of Virology 2007, 81:3904-3912.
21. Saif L.J., Ward L.A., Yuan L., Rosen B.I., To T.L. The gnotobiotic piglet as a model for studies of disease pathogenesis and immunity to human rotaviruses. Archives of Virology 1996, 12:S153-S161.
22. Iosef C., Van Nguyen T., Jeong K., Bengtsson K., Morein B., Kim Y., et al. Systemic and intestinal antibody secreting cell responses and protection in gnotobiotic pigs immunized orally with attenuated Wa human rotavirus and Wa 2/6-rotavirus-like-particles associated with immunostimulating complexes. Vaccine 2002, 20:1741-1753.
23. Esona MD, Foytich K, Wang Y, Shin G, Wei G, Gentsch JR, et al. Molecular characterization of human rotavirus vaccine strain CDC-9 during sequential passages in Vero cells. Human Vaccines 2010.
24. Jiang B., Wang Y., Saluzzo J.F., Bargeron K., Frachette M.J., Glass R.I. Immunogenicity of a thermally inactivated rotavirus vaccine in mice. Human Vaccines 2008, 4:143-147.
25. Ward L.A., Rosen B.I., Yuan L., Saif L.J. Pathogenesis of an attenuated and a virulent strain of group A human rotavirus in neonatal gnotobiotic pigs. Journal of General Virology 1996, 77:1431-1441.
26. Padilla-Noriega L., Werner-Eckert R., Mackow E.R., Gorziglia M., Larralde G., Taniguchi K., et al. Serologic analysis of human rotavirus serotypes P1A and P2 by using monoclonal antibodies. Journal of Clinical Microbiology 1993, 31:622-628.
27. Yoder J.D., Dormitzer P.R., Yoder J.D., Dormitzer P.R. Alternative intermolecular contacts underlie the rotavirus VP5* two- to three-fold rearrangement. EMBO Journal 2006, 25:1559-1568.
28. Yoder J.D., Trask S.D., Vo P.T., Binka M., Feng N., Harrison S.C., et al. VP5 rearranges when rotavirus uncoats. Journal of Virology 2009, 83:11372-11377.
29. Welter M.W., Welter C.J. Evaluation of killed and modified live porcine rotavirus vaccines in cesarean derived colostrum deprived pigs. Veterinary Microbiology 1990, 22:179-186.
30. Yuan L.J., Kang S.Y., Ward L.A., To T.L., Saif L.J. Antibody secreting cell responses and protective immunity assessed in gnotobitoic pigs inoculated orally or intramuscularly with inactivated human rotavirus. Journal of Virology 1998, 72:330-338.
31. Zissis G., Lambert J.P., Marbehant P., Marissens D., Lobmann M., Charlier P., et al. Protective studies in colostrum-deprived piglets of a bovine rotavirus vaccine candidate using human rotavirus strains for challenge. Journal of Infectious Diseases 1983, 148:1061-1068.
32. Correia J.B., Patel M.M., Nakagomi O., Montenegro F.M.U., Germano E.M., Correia N.B., et al. Effectiveness of monovalent rotavirus vaccine (Rotarix) against severe diarrhea caused by serotypically unrelated G2P[4] strains in Brazil. Journal of Infectious Diseases 2010, 201:363-369.
33. Brice G.T., Dobano C., Sedegah M., Stefaniak M., Graber N.L., Campo J.J., et al. Extended immunization intervals enhance the immunogenicity and protective efficacy of plasmid DNA vaccines. Microbes & Infection 2007, 9:1439-1446.
34. Pittman P.R., Mangiafico J.A., Rossi C.A., Cannon T.L., Gibbs P.H., Parker G.W., et al. Anthrax vaccine: increasing intervals between the first two doses enhances antibody response in humans. Vaccine 2000, 19:213-216.
35. Silfverdal S.A., Ehlin A., Montgomery S.M. Protection against clinical pertussis induced by whole-cell pertussis vaccination is related to primo-immunisation intervals. Vaccine 2007, 25:7510-7515.
36. Centers for Disease Control Prevention Intussusception among recipients of rotavirus vaccine - United States, 1998-1999. Morbidity & Mortality Weekly Report 1999, 48:577-581.
37. Centers for Disease Control Prevention Postmarketing monitoring of intussusception after RotaTeq vaccination - United States, February 1, 2006-February 15, 2007. Morbidity & Mortality Weekly Report 2007, 56:218-222.